Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

Company AnnouncementJohnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture ...

Genmab A/S (Nasdaq: GMAB) said on Monday that Johnson & Johnson (J&J) has decided not to exercise its option to obtain a ...

Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to ...

Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.

Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.

Last year, J&J licensed a follow-up to Darzalex from Genmab, HexaBody-CD38, that it says could be used in Darzalex-resistant patients as well as in other cancer indications beyond myeloma ...

Last year, J&J licensed a follow-up to Darzalex from Genmab, HexaBody-CD38, that it says could be used in Darzalex-resistant patients as well as in other cancer indications beyond myeloma ...

The decision comes after Genmab provided J&J with data from a clinical proof-of-concept study, which included a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) in ...

The stock has rebounded since the earnings report, but it was under pressure since my previous update as investors and traders contemplate the fate of GEN3014, the next-generation CD38 HexaBody on ...

The upgrade reflects a positive long-term outlook despite expectations that Johnson & Johnson (JNJ) is unlikely to opt-in for GEN3014 (Hexabody-CD38), a decision anticipated within the first ...